Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
Chan Zuckerberg Biohub, San Francisco, California, USA.
J Infect Dis. 2023 Jan 11;227(2):246-250. doi: 10.1093/infdis/jiac372.
Interferon (IFN)-specific autoantibodies have been implicated in severe coronavirus disease 2019 (COVID-19) and have been proposed as a potential driver of the persistent symptoms characterizing "long COVID," a type of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We report that only 2 of 215 participants with convalescent SARS-CoV-2 infection tested over 394 time points, including 121 people experiencing long COVID symptoms, had detectable IFN-α2 antibodies. Both had been hospitalized during the acute phase of the infection. These data suggest that persistent anti-IFN antibodies, although a potential driver of severe COVID-19, are unlikely to contribute to long COVID symptoms in the postacute phase of the infection.
干扰素（IFN）特异性自身抗体与严重的 2019 年冠状病毒病（COVID-19）有关，并被认为是导致“长新冠”持续症状的潜在驱动因素，“长新冠”是严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染后出现的一种急性后遗症。我们报告称，在对 215 名 SARS-CoV-2 恢复期感染患者进行的 394 多次检测中，仅有 2 人检测到可检测到的 IFN-α2 抗体，其中 121 人有长新冠症状。这两人均在感染急性期住院。这些数据表明，尽管持续的抗 IFN 抗体可能是 COVID-19 严重程度的一个潜在驱动因素，但不太可能导致感染后急性期的长新冠症状。
